Trial Profile
A randomized controlled trial of two versus three doses of Rotarix vaccine for boosting and longevity of vaccine immune responses in Zambia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2019
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- Acronyms ROVAS-2
- 16 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 New trial record